Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
UK cell therapy biotech bit.bio pivots to tool development, forms partnership with BlueRock Therapeutics
Mar 19, 2025
Contract Type
partnership
CambridgeshireInformation TechnologyFinancial ServicesSoftwareScience And EngineeringPayments
Description
UK cell therapy biotech bit.bio has laid off 25% of its staff and shifted focus to biomedical tools over drug development. The company is partnering with Bayer’s BlueRock Therapeutics to develop ioCells, human cells programmed from induced pluripotent stem cells, to reduce variance and timelines for researchers.
Quick answer
UK cell therapy biotech bit.bio pivots to tool development, forms partnership with BlueRock Therapeutics (March 19, 2025). bit.bio is based in Cambridgeshire, England, United Kingdom.
What agreement did bit.bio announce on March 19, 2025?
UK cell therapy biotech bit.bio has laid off 25% of its staff and shifted focus to biomedical tools over drug development. The company is partnering with Bayer’s BlueRock Therapeutics to develop ioCells, human cells programmed from induced pluripotent stem cells, to reduce variance and timelines for researchers.
What does bit.bio do?
bit.bio is an award-winning human synthetic biology company - our mission: coding cells for novel cures.
Where is bit.bio based?
bit.bio is based in Cambridgeshire, England, United Kingdom.
Source: Fundz verified event record.
Company Information
Company
bit.bio
Location
Cambridgeshire, England, United Kingdom
About
bit.bio is an award-winning human synthetic biology company - our mission: coding cells for novel cures.
We have developed an end-to-end platform for the creation of any human cell type. With our cutting-edge and patent-protected opti-ox precision cell programming technology, we can deterministically program human iPSCs into a chosen cell identity with unprecedented biological consistency at an industrial scale, and approximately 10 times faster than conventional methods. Our platform has the potential to unlock a new generation of medicines.
Our io Cells research products provide scientists access to highly characterised, consistent, scalable human cells that enable research and drug discovery teams to accelerate their experimental timelines and reduce experimental variability, providing an important alternative to traditional workflows. We are also leveraging our platform to build a pipeline of txCells for cell therapies.
To achieve our goals, we have assembled a team of pioneers in stem cell biology, cell programming, mathematical modelling and cell therapy. We are empirical, highly ambitious and driven by a shared vision.
Collaboration is at the heart of bit.bio. Join us on our journey.